[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583784":3},{"organization":4,"outcomesModule":7,"designInfo":59,"detailedDescription":65,"studyPopulation":13,"armGroups":66,"interventions":80,"overallOfficials":84,"centralContacts":93,"locations":99,"responsibleParty":148,"collaborators":150,"id":158,"slug":13,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":159,"sex":165,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":13,"studyType":171,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":102,"whyStopped":13,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"Jaeb Center for Health Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":14},[9],{"measure":10,"description":11,"timeFrame":12},"Blood glucose \u003C70 mg\u002FdL","Blood glucose \\\u003C70 mg\u002FdL within 90 minutes from the start of exercise","90 minutes",null,[15,18,21,24,27,30,33,36,39,42,46,50,53,56],{"measure":16,"description":17,"timeFrame":12},"Exploratory Efficacy Outcome: Change in blood glucose from exercise start to nadir glucose","Change in blood glucose from exercise start to nadir glucose within 90 minutes from start of exercise",{"measure":19,"description":20,"timeFrame":12},"Exploratory Efficacy Outcome: Change in CGM glucose from exercise start to nadir glucose","Change in CGM glucose from exercise start to nadir glucose within 90 minutes from start of exercise",{"measure":22,"description":23,"timeFrame":12},"Exploratory Efficacy Outcome: Time in range 70-180 mg\u002FdL","Time in range 70-180 mg\u002FdL within 90 minutes from start of exercise",{"measure":25,"description":26,"timeFrame":12},"Exploratory Efficacy Outcome: Time in tight range 70-140 mg\u002FdL","Time in tight range 70-140 mg\u002FdL within 90 minutes from start of exercise",{"measure":28,"description":29,"timeFrame":12},"Exploratory Efficacy Outcome: Mean glucose","Mean glucose within 90 minutes from start of exercise",{"measure":31,"description":32,"timeFrame":12},"Exploratory Efficacy Outcome: CGM glucose \u003C54 mg\u002FdL","CGM glucose \\\u003C54 mg\u002FdL within 90 minutes from start of exercise",{"measure":34,"description":35,"timeFrame":12},"Exploratory Efficacy Outcome: CGM glucose \u003C70 mg\u002FdL","CGM glucose \\\u003C70 mg\u002FdL within 90 minutes from start of exercise",{"measure":37,"description":38,"timeFrame":12},"Exploratory Efficacy Outcome: CGM glucose >250 mg\u002FdL","CGM glucose \\>250 mg\u002FdL within 90 minutes from start of exercise",{"measure":40,"description":41,"timeFrame":12},"Exploratory Efficacy Outcome: CGM glucose >300 mg\u002FdL","CGM glucose \\>300 mg\u002FdL within 90 minutes from start of exercise",{"measure":43,"description":44,"timeFrame":45},"Safety Outcome: Severe hypoglycemia events","Defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions","From enrollment to last clinic visit (up to ~12 weeks)",{"measure":47,"description":48,"timeFrame":49},"Safety Outcome: Blood glucose \u003C54 mg\u002FdL during clinic","Blood glucose \\\u003C54 mg\u002FdL between start of meal and discharge from clinic","210 minutes",{"measure":51,"description":52,"timeFrame":49},"Safety Outcome: Blood glucose \u003C70 mg\u002FdL during clinic","Blood glucose \\\u003C70 mg\u002FdL between start of meal and discharge from clinic",{"measure":54,"description":55,"timeFrame":45},"Safety Outcome: Adverse events related to exercise procedure","Adverse events related to the exercise procedure",{"measure":57,"description":58,"timeFrame":45},"Safety Outcome: Adverse events associated with technosphere insulin inhalation","Adverse events associated with technosphere insulin (TI) inhalation: hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing",{"allocation":60,"interventionModel":61,"interventionModelDescription":13,"primaryPurpose":62,"observationalModel":13,"timePerspective":13,"maskingInfo":63},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":64,"maskingDescription":13,"whoMasked":13},"NONE","The study is a 3-period randomized crossover trial, each with a structured afternoon exercise session following a standard lunch meal. The 3 sessions are as follows: (1) TI for meal bolus with pump in sleep mode, (2) RAA for meal bolus with pump in sleep mode, and (3) RAA for meal bolus with pump in standard mode with transition to exercise mode one hour before start of exercise. The study is being done to compare the efficacy and safety of TI versus RAA given as bolus for meal prior to initiating aerobic exercise in adults ≥18 to ≤ 65 years of age with T1D using Control-IQ.\n\nAll participants will complete 3 exercise sessions, with the order determined through randomization.",[67,73,77],{"label":68,"type":69,"description":70,"interventionNames":71},"Control IQ + sleep activity with TI","EXPERIMENTAL","TI for meal bolus with Control IQ + sleep activity pump setting",[72],"Device: Control IQ + sleep activity with TI",{"label":74,"type":75,"description":76,"interventionNames":13},"Control IQ + sleep activity with Rapid-Acting Analogue (RAA) Comparator","NO_INTERVENTION","RAA for meal bolus with with Control IQ + sleep activity pump setting",{"label":78,"type":75,"description":79,"interventionNames":13},"Control IQ + exercise activity with Rapid-acting analogue (RAA) Control","RAA for meal bolus with Control IQ pump setting with transition to Control IQ + exercise activity pump setting one hour before start of exercise",[81],{"type":82,"name":68,"description":70,"armGroupLabels":83,"otherNames":13},"DEVICE",[68],[85,89],{"name":86,"affiliation":87,"role":88},"Michael R Rickels, MD, MA","University of Pennsylvania","PRINCIPAL_INVESTIGATOR",{"name":90,"affiliation":91,"role":92},"Michael Ridell, PhD","York University","STUDY_CHAIR",[94],{"name":95,"role":96,"phone":97,"phoneExt":13,"email":98},"Robin Gal, MSPH","CONTACT","813-975-8690","rgal@jaeb.org",[100,119,133],{"facility":101,"status":102,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":113,"contacts":114},"University of Louisville","RECRUITING","Louisville","Kentucky","40202","United States","US",{"type":109,"coordinates":110},"Point",[111,112],-85.75941,38.25424,{"lat":112,"lon":111},[115],{"name":116,"role":96,"phone":117,"phoneExt":13,"email":118},"Taylor Hendryx","502-861-4608","taylor.hendryx@nortonhealthcare.org",{"facility":87,"status":102,"city":120,"state":121,"zip":122,"country":106,"countryCode":107,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Philadelphia","Pennsylvania","19104",{"type":109,"coordinates":124},[125,126],-75.16362,39.95238,{"lat":126,"lon":125},[129],{"name":130,"role":96,"phone":131,"phoneExt":13,"email":132},"Wendy Yang","215-746-8136","T1D@pennmedicine.upenn.edu",{"facility":134,"status":102,"city":135,"state":136,"zip":137,"country":106,"countryCode":107,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"University of Washington","Seattle","Washington","98195",{"type":109,"coordinates":139},[140,141],-122.33207,47.60621,{"lat":141,"lon":140},[144],{"name":145,"role":96,"phone":146,"phoneExt":13,"email":147},"Dori Khakpour","206-945-4965","dorik@uw.edu",{"type":149,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[151,154,156],{"name":152,"class":153},"Mannkind Corporation","INDUSTRY",{"name":155,"class":153},"Tandem Diabetes Care, Inc.",{"name":157,"class":6},"The Leona M. and Harry B. Helmsley Charitable Trust","100583784",false,"NCT06880835","Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery","INHALE-AIDEx: A Randomized Crossover Trial Evaluating the Effect of Inhaled Technosphere Insulin (Afrezza®) vs Rapid Acting Analogue Insulin on Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes Using Automated Insulin Delivery","INHALE-AIDEx","Inclusion Criteria:\n\n1. Ability to provide informed consent for study participation\n2. Age ≥18 years to 65 years\n3. Clinical diagnosis of T1D (per the Investigator)\n4. Using Tandem t:slim X2 or Tandem Mobi insulin pump with Control-IQ for at least 90 days prior to screening visit\n5. Using insulin aspart or insulin lispro in Tandem insulin pump\n6. Total daily insulin dose 20 to 80 units\n7. Usual RAA insulin bolus for 50 gram carbohydrate lunch meal is ≤12 units\n8. Physically active, with at least 3 moderate or vigorous exercise sessions ≥30 minutes per typical week self-reported by participant\n9. No medical, psychiatric, or other conditions, or medications being taken that in the Investigator's judgement would be a safety concern for participation in the study\n10. No electrocardiogram (ECG) abnormality that in the judgment of the investigator, which will take into consideration the usual exercise performed by the participant and their overall medical condition, increases the risk of exercise\n11. Investigator believes that the participant can safely follow the protocol\n12. Able to read and understand written and spoken English or Spanish\n\nExclusion Criteria:\n\n1. Use of inhaled insulin within one week prior to screening visit\n2. History of asthma, chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator\n3. Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 90 days prior to screening visit and no plans to smoke during the study\n4. History or current diagnosis of lung cancer\n5. Forced expiratory volume in 1 second (FEV1) measurement of \\\u003C70% of predicted Global Lung Function Initiative value\n6. Pregnant or lactating, planning to become pregnant during the study, or is of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral\u002Finjectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)\n\n   • A pregnancy test is required for any person of childbearing potential.\n7. An event of severe hypoglycemia, as judged by the Investigator, within the 90 days prior to screening visit\n8. An episode of diabetic ketoacidosis (DKA) as defined in section 5.2 within the 90 days prior to screening visit\n9. Any disease other than diabetes or current use (or anticipated use during the study) of any medication (e.g., beta blocker) that, in the judgment of the Investigator, may substantially impact glucose metabolism\n10. Use of a non-insulin glucose-lowering medication (or weight-reduction medication with glucose-lowering effect) within 4 weeks prior to screening visit\n11. Exposure to any investigational drug in the 90 days prior to the screening visit\n12. Current or anticipated acute uses of oral, inhaled, or injectable glucocorticoids during the time period of the study (topical or intranasal glucocorticoid use is acceptable)\n13. Current use of Hydroxyurea medication\n14. Current or anticipated use of a low carbohydrate diet (\\\u003C50 grams\u002Fday) or low calorie diet (\\\u003C800 kcal\u002Fday) during the time period of the study\n15. Current treatment for diabetic retinopathy\n16. Known stage 4\u002F5 chronic kidney disease or on dialysis\n17. Having a direct supervisor at place of employment who is directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the study","ALL","18 Years","65 Years",{"count":169,"type":170},30,"ESTIMATED","INTERVENTIONAL",[173],"NA","This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology (\"Control-IQ\" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to complete three study exercise visits in the clinic.",[176],"Diabetes Mellitus, Type 1",[176,178,179,180],"Exercise","Technosphere Insulin","Automated Insulin Delivery","2025-09-18",{"date":183,"type":184},"2025-09-23","ACTUAL",{"date":186,"type":184},"2025-06-05",{"date":188,"type":170},"2026-05-31",{"name":5,"class":6},3]